Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

21. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Executive Summary 1 Translation of the executive summary of the final report “Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen” (Version 1.0; Status: 3 September 2013). Please note: This translation is provided as a service by IQWiG to English-language (...) readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. G09-01 Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments 1 Executive summary of final report G09-01 Version 1.0 Health economic evaluation of venlafaxine, duloxetine, bupropion, mirtazapine 3 Sep 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

22. Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. Full Text available with Trip Pro

Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. 22986399 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. JC3-7 10.7326/0003-4819-157-6-201209180-02007 Prochazka Allan V AV Caverly Tanner J TJ eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Cochrane

2012 Annals of Internal Medicine

23. Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome Full Text available with Trip Pro

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome Smokers hospitalized with acute coronary syndrome (ACS) are at high risk for subsequent ischemic events. Nevertheless, over two-thirds of patients continue to smoke after an acute myocardial infarction. Bupropion hydrochloride has proven efficacy as a smoking cessation aid, but data regarding its safety and efficacy in ACS patients are limited.In a double-blind, randomized controlled trial, we compared the safety (...) and efficacy of 8 weeks of treatment with bupropion slow-release (SR) or placebo for smokers hospitalized with ACS as an adjunct to nurse-led hospital- and telephone-based support. Primary efficacy outcome was smoking abstinence at 1 year. Primary safety outcome was clinical events at 1 year.A total of 151 patients were enrolled; all but 2 completed follow-up. Abstinence rates at 3 months were 45% and 44% in the bupropion SR and placebo groups, respectively (P = .99); 37% vs 42% (P = .61) at 6 months

2011 EvidenceUpdates Controlled trial quality: predicted high

24. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.1; Status: 30.05.2011). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression 30.05.2011 Institute for Quality and Efficiency in Health Care (IQWiG) Version 1.1 - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal

2011 Institute for Quality and Efficiency in Healthcare (IQWiG)

25. Forfivo XL (bupropion hydrochloride 450 mg extended-release) tablets

Forfivo XL (bupropion hydrochloride 450 mg extended-release) tablets Drug Approval Package: Forfivo XL (bupropion hydrochloride) NDA #022497 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - FORFIVO XL (bupropion hydrochloride 450 mg extended-release) tablets Company: IntelGenx Corp Application No.: 022497 Approval Date: 11/10/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

2011 FDA - Drug Approval Package

26. Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. (Abstract)

Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. 20436150 2010 05 05 2017 01 23 1468-9618 13 2 2010 Apr Evidence-based nursing Evid Based Nurs Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine

2010 Evidence-Based Nursing Controlled trial quality: uncertain

27. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (Abstract)

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Despite increasing public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed (...) naltrexone 32 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB32), sustained-release naltrexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB16), or matching placebo twice a day, given orally for 56 weeks. The trial included a 3-week dose escalation. Randomisation was done by use of a centralised, computer-generated, web-based system and was stratified by study centre. Co-primary

2010 Lancet Controlled trial quality: predicted high

28. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Full Text available with Trip Pro

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of varenicline compared with bupropion or no aid for smoking cessation in Finland. The authors concluded that varenicline was more effective and resulted in cost savings

2010 NHS Economic Evaluation Database.

29. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse

Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions RCTs examining the efficacy of bupropion in adult ADHD frequently reported

2010 Health Technology Assessment (HTA) Database.

30. Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Full Text available with Trip Pro

Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Article Text Therapeutics Review: bupropion increases

2010 Evidence-Based Mental Health

31. Use of bupropion in patients with depression and the associated risk of seizures: safety

Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Use of bupropion in patients with depression and the associated risk of seizures: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The available evidence of an increased risk of seizures in patients treated with bupropion for depression was inconclusive. This evidence was, however, limited to uncontrolled studies rated as low quality by the authors of the AHRQ

2010 Health Technology Assessment (HTA) Database.

32. Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder

Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after (...) the failure of an SSRI for major depressive disorder Leelahanaj T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of switching from citalopram to bupropion monotherapy versus bupropion in addition

2010 NHS Economic Evaluation Database.

33. Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months

Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 monthsCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 monthsCommentary Article

2010 Evidence-Based Nursing

34. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.0; Status: 09.11.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression Version 1.0 09.11.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-20C Publisher’s address: Institute for Quality

2009 Institute for Quality and Efficiency in Healthcare (IQWiG)

35. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Full Text available with Trip Pro

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Hoogendoorn M, Welsing P, Rutten-van Molken M P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the long-term cost-effectiveness of varenicline to support smoking cessation in comparison with no treatment, bupropion, nortriptyline, or nicotine-replacement therapy (NRT). The authors concluded that varenicline was cost-effective compared

2008 NHS Economic Evaluation Database.

36. Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Full Text available with Trip Pro

Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Bolin K, Mork A C, Willers S, Lindgren B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of varenicline in comparison with bupropion in smoking-cessation programmes for smokers aged 18 years or older. The authors concluded that varenicline was a cost-effective alternative to bupropion in Sweden. The study was based on robust methodology, which enhances the validity

2008 NHS Economic Evaluation Database.

37. Review: bupropion and nortriptyline each increase smoking cessation rates Full Text available with Trip Pro

Review: bupropion and nortriptyline each increase smoking cessation rates Review: bupropion and nortriptyline each increase smoking cessation rates | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: bupropion and nortriptyline each increase smoking cessation rates Article Text Therapeutics Review: bupropion and nortriptyline each increase smoking cessation rates Free Allan V Prochazka , MD, MSc Statistics from Altmetric.com Hughes JR

2006 Evidence-Based Medicine

38. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. Full Text available with Trip Pro

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 (...) weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory

2006 NEJM Controlled trial quality: uncertain

39. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Full Text available with Trip Pro

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation.To assess efficacy and safety of varenicline for smoking cessation compared (...) with sustained-release bupropion (bupropion SR) and placebo.Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising.Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline

2006 JAMA Controlled trial quality: predicted high

40. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Full Text available with Trip Pro

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine.To determine the efficacy and safety of varenicline for smoking cessation compared (...) with placebo or sustained-release bupropion (bupropion SR).A randomized, double-blind, placebo-controlled trial conducted between June 2003 and March 2005 at 14 research centers with a 12-week treatment period and follow-up of smoking status to week 52. Of 1413 adult smokers who volunteered for the study, 1027 were enrolled; 65% of randomized participants completed the study.Varenicline titrated to 1 mg twice daily (n = 344) or bupropion SR titrated to 150 mg twice daily (n = 342) or placebo (n = 341

2006 JAMA Controlled trial quality: predicted high